Trust linked to Cocrystal (COCP) director buys 50,000 shares

Rhea-AI Filing Summary

Cocrystal Pharma director-affiliated trust buys additional shares. An entity associated with director and 10% owner Phillip Frost reported purchasing 50,000 shares of Cocrystal Pharma common stock on 02/06/2026 at a weighted average price of $0.9456 per share, with trades ranging from $0.8899 to $0.9880.

After this transaction, Frost Gamma Investments Trust is reported as indirectly holding 1,888,551 shares. Separately, 27,100 shares are held directly, including common stock issuable upon vesting of restricted stock units. Dr. Frost disclaims beneficial ownership of the trust-held and certain other shares except to the extent of any pecuniary interest.

Insider Trade Summary

Net Buyer: 50,000 shares ($47,280)

Net Buy 2 txns

Insider FROST PHILLIP MD ET AL

Role Director, 10% Owner

Bought 50,000 shs ($47K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	50,000	$0.9456	$47K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 1,888,551 shares (Indirect, By Frost Gamma Investments Trust); Common Stock — 27,100 shares (Direct)

Footnotes (1)

1. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions ranging from $0.8899 to $0.9880, inclusive. The reporting person undertakes to provide to Cocrystal Pharma, Inc., any security holder of Cocrystal Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares purchased at each separate price within the ranges set forth in the preceding sentence. These shares are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole stockholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is the sole stockholder of Frost-Nevada Corporation. The Reporting Person disclaims beneficial ownership of the securities held by Frost Gamma Investments Trust except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Includes shares of common stock issuable upon vesting of restricted stock units.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FROST PHILLIP MD ET AL

(Last) (First) (Middle)

4400 BISCAYNE BLVD

(Street)

MIAMI FL 33137-3227

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cocrystal Pharma, Inc. [ COCP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/06/2026		P		50,000	A	$0.9456(1)	1,888,551	I	By Frost Gamma Investments Trust(2)
Common Stock								27,100(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions ranging from $0.8899 to $0.9880, inclusive. The reporting person undertakes to provide to Cocrystal Pharma, Inc., any security holder of Cocrystal Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares purchased at each separate price within the ranges set forth in the preceding sentence.

2. These shares are held by Frost Gamma Investments Trust, of which Phillip Frost M.D., is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of Frost Gamma Investments Trust. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole stockholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is the sole stockholder of Frost-Nevada Corporation. The Reporting Person disclaims beneficial ownership of the securities held by Frost Gamma Investments Trust except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

3. Includes shares of common stock issuable upon vesting of restricted stock units.

Remarks:

This Form 4 does not include any of the securities owned directly by OPKO Health, Inc., a company of which Dr. Frost is the Chairman of the Board and Chief Executive Officer, concerning the securities of which Dr. Frost does not hold voting and investment control. Dr. Frost disclaims beneficial ownership of the securities held by OPKO Health, Inc. except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that Dr. Frost is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

	/s/ Phillip Frost, MD ET AL	02/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did COCP report for Phillip Frost on February 6, 2026?

Cocrystal Pharma reported that an entity associated with director and 10% owner Phillip Frost bought 50,000 COCP common shares on February 6, 2026 at a weighted average price of $0.9456, with individual trades occurring between $0.8899 and $0.9880 per share.

Who actually holds the newly purchased COCP shares reported for Phillip Frost?

The 50,000 Cocrystal Pharma shares are held by Frost Gamma Investments Trust, where Phillip Frost is trustee. The filing explains a multi-entity ownership chain and states that Frost disclaims beneficial ownership of the trust’s securities except to the extent of any pecuniary interest.

How many COCP shares are indirectly and directly held after the reported transaction?

Following the transaction, Frost Gamma Investments Trust is reported as indirectly holding 1,888,551 Cocrystal Pharma shares. In addition, 27,100 shares are held directly, which the filing notes include common stock issuable upon vesting of restricted stock units granted to the reporting person.

What price range applied to the 50,000 COCP shares purchased through the trust?

The 50,000 Cocrystal Pharma shares were acquired at a weighted average price of $0.9456 per share. The filing states these purchases occurred in multiple trades at prices ranging from $0.8899 to $0.9880, and detailed trade data is available upon request from the company or regulator.

How does the Form 4 describe Phillip Frost’s beneficial ownership of COCP shares?

The Form 4 explains that Phillip Frost is trustee of Frost Gamma Investments Trust but disclaims beneficial ownership of its Cocrystal Pharma securities beyond any pecuniary interest. It similarly notes that shares owned by OPKO Health, Inc. are not included because Frost does not hold voting or investment control.

What does the Form 4 say about restricted stock units related to COCP shares?

The filing notes that the 27,100 directly held shares include Cocrystal Pharma common stock issuable upon vesting of restricted stock units. This means part of the reported direct position represents awards that will convert into shares upon satisfying vesting conditions specified in the grant agreements.